$2.10
+0.06 (+2.94%)
Open$2.06
Previous Close$2.04
Day High$2.15
Day Low$2.04
52W High$5.74
52W Low$1.11
Volume—
Avg Volume341.4K
Market Cap35.50M
P/E Ratio—
EPS$-1.57
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,137.1% upside
Current
$2.10
$2.10
Target
$25.98
$25.98
$20.93
$25.98 avg
$39.39
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.75M | 4.21M | 3.91M |
| Net Income | 909.1K | 778.9K | 578.2K |
| Profit Margin | 19.1% | 18.5% | 14.8% |
| EBITDA | 1.38M | 1.12M | 1.11M |
| Free Cash Flow | 932.9K | 1.05M | 869.6K |
| Rev Growth | +21.8% | +17.5% | +9.1% |
| Debt/Equity | 0.24 | 0.30 | 0.25 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |